94 related articles for article (PubMed ID: 2229925)
21. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
Sensi ML; Parenza M; Parmiani G
J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
[TBL] [Abstract][Full Text] [Related]
22. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
23. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts.
Shimizu J; Zou JP; Ikegame K; Katagiri T; Fujiwara H; Hamaoka T
J Immunol; 1991 Mar; 146(5):1708-14. PubMed ID: 1993850
[TBL] [Abstract][Full Text] [Related]
24. Enrichment of antitumor effector cells that are effective in vivo from spleen cells of tumor-bearing mice through the use of Dolichos biflorus lectin.
Okada T; Ezawa K; Imai Y; Osawa T
Cancer Res; 1986 Nov; 46(11):5611-7. PubMed ID: 3093067
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
26. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
27. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
Li T; Harada M; Tamada K; Abe K; Nomoto K
Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
[TBL] [Abstract][Full Text] [Related]
28. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
Dye ES
J Immunol; 1986 Feb; 136(4):1510-5. PubMed ID: 3080526
[TBL] [Abstract][Full Text] [Related]
29. Effect of Nocardia rubra cell wall skeleton on T-cell-mediated cytotoxicity in mice bearing syngeneic sarcoma.
Kawase I; Uemiya M; Yoshimoto T; Ogura T; Hirao F; Yamamura Y
Cancer Res; 1981 Feb; 41(2):660-6. PubMed ID: 6969630
[TBL] [Abstract][Full Text] [Related]
30. Increase in immunogenicity and sensitivity to natural cell-mediated cytotoxicity following in vitro exposure of MCA105 tumor cells to ultraviolet radiation.
Begovic M; Herberman R; Gorelik E
Cancer Res; 1991 Oct; 51(19):5153-9. PubMed ID: 1913641
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes.
Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
J Immunol; 1997 May; 158(10):4846-54. PubMed ID: 9144500
[TBL] [Abstract][Full Text] [Related]
32. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
Miki S; Ksander B; Streilein JW
Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
34. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
35. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
37. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
[TBL] [Abstract][Full Text] [Related]
38. [Antitumor effect of a novel antitumor compound, NC-190, in the double grafted tumor system].
Ebina T; Shishido K; Murata K
Gan To Kagaku Ryoho; 1990 Jul; 17(7):1345-50. PubMed ID: 2369138
[TBL] [Abstract][Full Text] [Related]
39. Prolongation of concomitant antitumor immunity in mice treated with Z-100, an arabinomannan extracted from Mycobacterium tuberculosis.
Sasaki H; Schmitt DA; Kobayashi M; Hayashi Y; Pollard RB; Suzuki F
Nat Immun; 1993; 12(3):152-64. PubMed ID: 8329838
[TBL] [Abstract][Full Text] [Related]
40. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice.
Saito M; Nanjo M; Kataoka M; Moriya Y; Sugawara Y; Yoshida T; Ishida N
Cancer Res; 1988 Aug; 48(15):4163-7. PubMed ID: 3390809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
